Quote: ------------------------------------------
Post# of 30028
Posted On: 10/16/2014 8:41:02 PM
Quote:
"All the above makes MANF an attractive development candidate for a larger pharmaceutical company seeking in-licensing opportunities in rare ocular diseases."
"The market exclusivity and strong pricing power conferred by the granting of a U.S. FDA Orphan Drug Destination make things attractive from a partnering standpoint."
"Companies that are marketing drugs targeting ocular diseases include Regeneron, Novartis/Alcon, Pfizer, Roche, and Bayer. We expect the U.S. FDA to respond to Amarantus ODD application in early 2015."
http://bionapcfa.blogspot.com/2014/10/amarant...ation.html
"All the above makes MANF an attractive development candidate for a larger pharmaceutical company seeking in-licensing opportunities in rare ocular diseases."
"The market exclusivity and strong pricing power conferred by the granting of a U.S. FDA Orphan Drug Destination make things attractive from a partnering standpoint."
"Companies that are marketing drugs targeting ocular diseases include Regeneron, Novartis/Alcon, Pfizer, Roche, and Bayer. We expect the U.S. FDA to respond to Amarantus ODD application in early 2015."
http://bionapcfa.blogspot.com/2014/10/amarant...ation.html
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼